CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients
NCT ID: NCT04512118
Last Updated: 2020-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2020-03-15
2020-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Lung Inflammation With FDG PET/CT in COVID-19
NCT04441489
Low-Dose Chest CT (LDCT) COVID-19 Study
NCT05031845
Prediction of Clinical Course in COVID19 Patients
NCT04377685
Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI
NCT05014516
Tomographic Findings in COVID-19 and Influenza
NCT04497311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET-CT of 18F-FDG
Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient affiliated to a social security scheme or equivalent
* adult patient having been informed of the study
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antoine VERGER
PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU of Nancy
Vandœuvre-lès-Nancy, Grand Est, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020PI153
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.